| Similar Articles |
|---|
 |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.   |
Pharmaceutical Executive
October 1, 2005
Fine & Meyer |
An 11-Step Program to Navigating Partnerships Commercial partnerships are an effective way to differentiate both research institutes and biotech companies. It is critical to recognize that while financial return is the primary driver of a commercial partnership, the cultural fit can sustain its success. |
Search Engine Watch
February 15, 2011
Nichola Stott |
9 Ways to Work with Your Client's PR Agency It's the job of SEO and public relations agencies to deliver content and grow a relevant audience. While objectives and success metrics may differ, there is often (and more increasingly) a great deal of overlap in method. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
Chemistry World
February 7, 2013
Maria Burke |
GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Inc.
May 2005
Stephanie Clifford |
The Next Great Retail Idea: PR? A North Carolina entrepreneur sets his sights on creating the H&R Block of public relations. PR Store is a storefront marketing and PR firm for small businesses. |
Pharmaceutical Executive
April 1, 2007
Porth & Sillup |
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. |
Entrepreneur
October 2007
Robert Kiyosaki |
Media Master Seeking publicity? Learn the art of proper PR, and the press will come looking for you. |
Pharmaceutical Executive
May 1, 2007
Waseem Noor |
Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
Search Engine Watch
February 18, 2011
Lisa Buyer |
Social PR: 10 Ways to Do PR Better with Social Media Optimizing and blending your online public relations strategy with social media and SEO has never had so many robust options. Here are 10 ways a business can capitalize on the social PR opportunity. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
Bio-IT World
November 2005
Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. |
Pharmaceutical Executive
September 1, 2006
Eleanor O'Rangers |
Marketing to Professionals: Savvy Strategists Ahead-of-the-curve brand teams are bringing in medical experts with marketing knowledge. |
Pharmaceutical Executive
March 1, 2011
Andrea LaFountain |
Where have all the Scientists Gone? With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence. |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
Search Engine Watch
September 10, 2010
Nichola Stott |
PR Tools for Link Builders Many tools designed for public relations professionals also work well for link builders. Here are four ways you can build links using PR. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Pharmaceutical Executive
January 1, 2009
Jim Weiss |
The Communications Convergence There are three elements of communications that biotech has always lived with, which are now central to the survival of any biopharma company: transparency, speed, and focus. Here's how to make each one work for your company. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Pharmaceutical Executive
June 1, 2012
Amy Smith |
Marketing: Medical Devices vs. Pharma Understanding the differences between drug and device marketing can make or break the brand's promotional activities. |
Inc.
April 2007 |
Conflict is Key A PR person explains why conflict is key in a letter to her clients. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Bio-IT World
January 21, 2005 |
How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Pharmaceutical Executive
March 1, 2009
Porth & Sillup |
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. |
Entrepreneur
January 2004
Gwen Moran |
Marketing Buzz Get what you pay for with pay-for-placement PR. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Pharmaceutical Executive
February 1, 2007
John Smith |
Public Relations: Beef Up Clinical Trial Numbers Web-based public relations can make the difference in clinical-trial recruitment. |
Managed Care
February 2002
Ira Studin |
Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions... |
Pharmaceutical Executive
August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
D-Lib
Nov/Dec 2014
Laurence Lannom |
Editorial The changes in both scientific journal and data publication, too slow for some, too fast for others, continues to accelerate. |
The Motley Fool
May 12, 2009
Brian Orelli |
Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama. |
Bio-IT World
June 15, 2003
Bob Violino |
Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector |
Search Engine Watch
December 18, 2007
Greg Jarboe |
Blogs Are the New Trade Press Memo to the media relations director: Online publications and group blogs are the new trade press - and these new media that can generate web traffic as well as publicity. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
Information Today
Barbara Quint |
PR Newswire Teams with Relegence on NewsPrompt PR Newswire announced a new toolbar service designed to alert users "second-by-second" to financial and business news coming from the Web sites of some 20,000 sources. |
Inc.
May 1, 2010
Joyner & McCorvey |
How to Manage Your Own PR At start-ups, founders often wear many hats, including that of PR manager. Here are ten tips for running a successful public-relations campaign. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
